Investigational drug · Phase 2
IBI3014
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Unresectable Locally Advanced or Metastatic Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "IBI3014"
First trial start
2025
Apr 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI3014", any sponsor or status.
Conditions studied
As listed on its trial records.
- Unresectable Locally Advanced or Metastatic Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI3014" as an intervention, largest first.
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06974812 · 250 participants (planned) · Start Apr 18, 2025 · Primary completion Jun 30, 2026
Drug: IBI3014; IBI3014 and 6 more · For: Unresectable Locally Advanced or Metastatic Solid Tumors
Sites: Fuzhou, China; Changsha, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Unresectable Locally Advanced or Metastatic Solid Tumors
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYHA1813Phase 33 trials
Shanghai Runshi Pharmaceutical Technology Co., Ltd · Unresectable Locally Advanced or Metastatic Solid Tumors, High Grade Meningioma, Recurrent or Progressive High Grade Meningioma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.